Arterial hypertension, a tricky side of Parkinson's disease: Physiopathology and therapeutic features

Neurological Sciences

Volumn 34, Issue 5, 2013, Pages 621-627

  Mazza, Alberto ^a   Ravenni, Roberta ^a   Antonini, Angelo ^b   Casiglia, Edoardo ^c   Rubello, Domenico ^a   Pauletto, Paolo ^d  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b PARKINSON INSTITUTE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d University Hospital of Treviso   (Italy)

Author keywords

Blood pressure monitoring; Calcium channel blockers; Hypertension; Orthostatic hypotension; Parkinson disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUDROCORTISONE ACETATE; MIDODRINE; MONOAMINE OXIDASE INHIBITOR; NITRATE; SELEGILINE; TOLCAPONE;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HYPERTENSION; NONHUMAN; ORTHOSTATIC HYPERTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; PARKINSON DISEASE; RISK FACTORS;

EID: 84878018782     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-012-1251-2     Document Type: Review

References (70)

1. Lawes CM (2008) Vander Hoorn S, Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371:1513-1518
2. Gangavati A, Hajjar I, Quach L et al (2011) Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc 59:383-389
3. Paganini-Hill A (2001) Risk factors for Parkinson's disease: the leisure world cohort study. Neuroepidemiology 20:118-124
4. McCann SJ, LeCouteur DG, Green AC et al (1998) The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology 17:310-317
5. Herishanu YO, Medvedovski M, Goldsmith JR et al (2001) A case-control study of Parkinson's disease in urban population of southern Israel. Can J Neurol Sci 28:144-147
6. Tan EK, Tan C, Fook-Chong SM et al (2003) Dose dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci 216:163-167
7. Semchuk KM, Love EJ, Lee RG (1993) Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 43:1173-1180
8. Simon KC, Chen H, Schwarzschild M et al (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69:1688-1695
9. Miyake Y, Tanaka K, Fukushima W et al (2010) Fukuoka Kinki Parkinson's Disease Study Group. Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 293:82-86
10. Qiu C, Hu G, Kivipelto M et al (2011) Association of Blood Pressure and Hypertension With the Risk of Parkinson Disease: the National FINRISK Study. Hypertension 57:1094-1100
11. Biaggioni I, Robertson RM (2002) Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin 20:291-301
12. Goldstein DS, Pechnik S, Holmes C et al (2003) Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 42:136-142
13. Pirpiris M, Cox H, Esler M et al (1994) Mineralocorticoid induced hypertension and noradrenaline spillover in man. Clin Exp Hypertens 16:147-161
14. Low PA, Gilden JL, Freeman R et al (1997) Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277:1046-1051
15. Tipton KF (1997) Monoamine oxidase inhibitors and pressor response to dietary amines. Vopr Med Khim 43:494-503
16. Sigurdardóttir GR, Nilsson C, Odin P et al (2001) Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine. Acta Neurol Scand 104:92-96
17. Jordan J, Biaggioni I (2002) Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension. J Clin Hypertens 4:139-145
18. Pathak A, Senard JM (2006) Blood pressure disorders during Parkinson's disease: epidemiology, pathophysiology and management. Expert Rev Neurother 6:1173-1180
19. Ejaz AA, Sekhon IS, Munjal S (2006) Characteristic findings on 24 h ambulatory blood pressure monitoring in a series of patients with Parkinson's disease. Eur J Intern Med 17:417-420
20. Ejaz AA, Kazory A, Heinig ME (2007) 24 hour blood pressure monitoring in the evaluation of supine hypertension and orthostatic hypotension. J Clin Hypertens 9:952-955
21. Mancia G, De Backer G, Dominiczak A et al (2007) ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 25:1751-1762
22. Cuspidi C, Macca G, Sampieri L et al (2001) Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens 19:1539-1545
23. Hajjar I, Zhao P, Alsop D et al (2010) Association of blood pressure elevation and nocturnal dipping with brain atrophy, perfusion and functional measures in stroke and non stroke individuals. Am J Hypertens 23:17-23
24. Schmidt C, Berg D, Herting et al (2009) Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord 24:2136-2142
25. Cuspidi C, Sala C, Valerio C et al (2011) Nocturnal blood pressure in untreated essential hypertensives. Blood Press 20:335-341
26. Wimbiscus M, Kostenko O, Malone D (2010) MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med 77:859-882
27. Goldstein DS, Eldadah BA, Holmes C et al (2005) Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 46:1333-1339
28. Senard JM, Valet P, Durrieu G et al (1990) Adrenergic super-sensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest 20:613-619
29. Senard JM, Brefel-Courbon C, Rascol O et al (2001) Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 18:495-505
30. Galinier M, Senard JM, Valet P et al (1994) Relationship between arterial blood pressure disturbances and alpha adrenoceptor density. Clin Exp Hypertens 16:373-389
31. Mathias CJ (1995) The classification and nomenclature of autonomic disorders: ending chaos, resolving conflict and hopefully achieving clarity. Clin Autonom Res 5:307-310
32. Jacobsen TN, Morgan BJ, Scherrer U et al (1993) Relative contributions of cardiopulmonary and sinoaortic baroreflexes in causing sympathetic activation in the human skeletal muscle circulation during orthostatic stress. Circ Res 73:367-378
33. Sharabi Y, Li ST, Dendi R et al (2003) Neurotransmitter specificity of sympathetic denervation in Parkinson's disease. Neurology 60:1036-1039
34. Goldstein DS (2003) Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2:669-676
35. Goldstein DS, Holmes C, Dendi R et al (2002) Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58:1247-1255
36. Diedrich A, Jordan J, Tank J et al (2003) The sympathetic nervous system in hypertension: assessment by blood pressure variability and ganglionic blockade. J Hypertens 21:1677-1686
37. Barbic F, Perego F, Canesi M et al (2007) Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. Hypertension 49:120-126
38. Barone P, Antonini A, Colosimo C et al (2009) PRIAMO study group. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24:1641-1649
39. Scigliano G, Musicco M, Soliveri P et al (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184-1188
40. Grandinetti A, Morens DM, Reed D et al (1994) Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 139:1129-1138
41. del Hoyo P, García-Redondo A, de Bustos F et al (2010) Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease. BMC Neurol 19(10):95
42. Mortiboys H, Johansen KK, Aasly JO et al (2010) Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75:2017-2020
43. Barnum CJ, Tansey MG (2010) Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res 184:113-132
44. Guzman JN, Sanchez-Padilla J, Wokosin D et al (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468:696-700
45. Simuni T, Borushko E, Avram MJ et al (2010) Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disord 25:2863-2866
46. Munoz A, Rey P, Guerra MJ et al (2006) Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 51:112-120
47. Ritz B, Rhodes SL, Qian L et al (2010) L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 67:600-606
48. Chan CS, Guzman JN, Ilijic E et al (2007) Rejuvenation protects neurons in mouse models of Parkinson's disease. Nature 447:1081-1086
49. Rodnitzky RL (1999) Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 57:845-849
50. Daniel JR, Mauro VF (1995) Extrapyramidal symptoms associated with calcium channel blockers. Ann Pharmacother 29:73-75
51. Mena MA, Garcia de Yebenes MJ, Tabernero C et al (1995) Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 18:410-426
52. Ton TG, Heckbert SR, Longstreth WT Jr et al (2007) Calcium channel blockers and beta-blockers in relation to Parkinson's disease. Parkinsonism Relat Disord 13:165-169
53. Reardon KA, Mendelsohn FA, Chai SY et al (2000) The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust NZ J Med 30:48-53
54. Chang YP, Shih PY (2009) A case of Parkinson's disease worsened by captopril: an unexpected adverse effect. Mov Disord 24:790
55. Allen AM, MacGregor DP, Chai SY et al (1992) Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol 32:339-344
56. Brown DC, Steward LJ, Ge J, Barnes NM (1996) Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 118(414-420):90
57. Sarma GR, Kamath V, Mathew T et al (2008) A case of parkinsonism worsened by losartan: a probable new adverse effect. Mov Disord 23:1055
58. Becker C, Jick SS, Meier CR (2008) Use of antihypertensives and the risk of Parkinson disease. Neurology 70:1438-1444
59. Blob LF, Sharoky M, Campbell BJ et al (2007) Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 h. CNS Spectr 12:25-34
60. Heinonen EH, Myllylä V (1998) Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf 19:11-22
61. White WB, Salzman P (2008) Parkinson's Rasagiline: efficacy and Safety in the Treatment of Off Parkinson Study Group. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. Hypertension 52:587-593
62. Rojo A, Fontán A, Mena MA et al (2001) Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease. Parkinsonism Relat Disord 7:93-96
63. Naschitz JE, Slobodin G, Elias N, Rosner I (2006) The patient with supine hypertension and orthostatic hypotension: a clinical dilemma. Postgrad Med J 82:246-253
64. Mansoor GA (2006) Orthostatic hypotension due to autonomic disorders in the hypertension clinic. Am J Hypertens 19:319-326
65. Shibao C, Gamboa A, Diedrich A et al (2005) Management of hypertension in the setting of autonomic failure: a pathophysiological approach. Hypertension 45:469-476
66. Shibao C, Gamboa A, Abraham R et al (2006) Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension 47:522-526
67. Jordan J, Shannon JR, Pohar B et al (1999) Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 10:35
68. Mehlsen J, Trap-Jensen J (1990) Haemodynamics in postural hypotension - effects of the beta-adrenoceptor partial agonist xamoterol, and pindolol. Eur Heart J 11:56-58
69. Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69-72
70. Oldenburg O, Mitchell A, Nurnberger J et al (2001) Ambulatory norepinephrine treatment of severe autonomic orthostatic hypotension. J Am Coll Cardiol 37:219-223